"Tay-Sachs Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessive neurodegenerative disorder characterized by the onset in infancy of an exaggerated startle response, followed by paralysis, dementia, and blindness. It is caused by mutation in the alpha subunit of the HEXOSAMINIDASE A resulting in lipid-laden ganglion cells. It is also known as the B variant (with increased HEXOSAMINIDASE B but absence of hexosaminidase A) and is strongly associated with Ashkenazic Jewish ancestry.
| Descriptor ID |
D013661
|
| MeSH Number(s) |
C10.228.140.163.100.435.825.300.300.500 C16.320.565.189.435.825.300.300.500 C16.320.565.398.641.803.350.300.850 C16.320.565.595.554.825.300.300.840 C18.452.132.100.435.825.300.300.500 C18.452.584.687.803.350.300.850 C18.452.648.189.435.825.300.300.500 C18.452.648.398.641.803.350.300.850 C18.452.648.595.554.825.300.300.840
|
| Concept/Terms |
Tay-Sachs Disease- Tay-Sachs Disease
- Tay Sachs Disease
- GM2 Gangliosidosis, Type I
- Tay-Sachs Disease, B Variant
- Tay Sachs Disease, B Variant
- GM2-Gangliosidosis, Type I
- Type I GM2-Gangliosidosis
- B Variant GM2 Gangliosidosis
- B Variant GM2-Gangliosidosis
- B Variant GM2-Gangliosidoses
- GM2-Gangliosidosis, B Variant
- Deficiency Disease Hexosaminidase A
- G(M2) Gangliosidosis, Type I
- Gangliosidosis G(M2), Type I
- Gangliosidosis GM2 , Type 1
- Gangliosidosis GM2, B Variant
- Gangliosidosis GM2, Type I
- GM2 Gangliosidosis, B Variant
- GM2 Gangliosidosis, Type 1
- Hexosaminidase A Deficiency Disease
- Sphingolipidosis, Tay-Sachs
- Sphingolipidosis, Tay Sachs
- Tay-Sachs Sphingolipidosis
Hexosaminidase alpha-Subunit Deficiency (Variant B)- Hexosaminidase alpha-Subunit Deficiency (Variant B)
- Deficiency, Hexosaminidase alpha-Subunit (Variant B)
- Hexosaminidase alpha Subunit Deficiency (Variant B)
- Hexosaminidase A Deficiency
- Deficiency, Hexosaminidase A
- HexA Deficiency
|
Below are MeSH descriptors whose meaning is more general than "Tay-Sachs Disease".
- Diseases [C]
- Nervous System Diseases [C10]
- Central Nervous System Diseases [C10.228]
- Brain Diseases [C10.228.140]
- Brain Diseases, Metabolic [C10.228.140.163]
- Brain Diseases, Metabolic, Inborn [C10.228.140.163.100]
- Lysosomal Storage Diseases, Nervous System [C10.228.140.163.100.435]
- Sphingolipidoses [C10.228.140.163.100.435.825]
- Gangliosidoses [C10.228.140.163.100.435.825.300]
- Gangliosidoses, GM2 [C10.228.140.163.100.435.825.300.300]
- Tay-Sachs Disease [C10.228.140.163.100.435.825.300.300.500]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Genetic Diseases, Inborn [C16.320]
- Metabolism, Inborn Errors [C16.320.565]
- Brain Diseases, Metabolic, Inborn [C16.320.565.189]
- Lysosomal Storage Diseases, Nervous System [C16.320.565.189.435]
- Sphingolipidoses [C16.320.565.189.435.825]
- Gangliosidoses [C16.320.565.189.435.825.300]
- Gangliosidoses, GM2 [C16.320.565.189.435.825.300.300]
- Tay-Sachs Disease [C16.320.565.189.435.825.300.300.500]
- Lipid Metabolism, Inborn Errors [C16.320.565.398]
- Lipidoses [C16.320.565.398.641]
- Sphingolipidoses [C16.320.565.398.641.803]
- Gangliosidoses [C16.320.565.398.641.803.350]
- Gangliosidoses, GM2 [C16.320.565.398.641.803.350.300]
- Tay-Sachs Disease [C16.320.565.398.641.803.350.300.850]
- Lysosomal Storage Diseases [C16.320.565.595]
- Lysosomal Storage Diseases, Nervous System [C16.320.565.595.554]
- Sphingolipidoses [C16.320.565.595.554.825]
- Gangliosidoses [C16.320.565.595.554.825.300]
- Gangliosidoses, GM2 [C16.320.565.595.554.825.300.300]
- Tay-Sachs Disease [C16.320.565.595.554.825.300.300.840]
- Nutritional and Metabolic Diseases [C18]
- Metabolic Diseases [C18.452]
- Brain Diseases, Metabolic [C18.452.132]
- Brain Diseases, Metabolic, Inborn [C18.452.132.100]
- Lysosomal Storage Diseases, Nervous System [C18.452.132.100.435]
- Sphingolipidoses [C18.452.132.100.435.825]
- Gangliosidoses [C18.452.132.100.435.825.300]
- Gangliosidoses, GM2 [C18.452.132.100.435.825.300.300]
- Tay-Sachs Disease [C18.452.132.100.435.825.300.300.500]
- Lipid Metabolism Disorders [C18.452.584]
- Lipidoses [C18.452.584.687]
- Sphingolipidoses [C18.452.584.687.803]
- Gangliosidoses [C18.452.584.687.803.350]
- Gangliosidoses, GM2 [C18.452.584.687.803.350.300]
- Tay-Sachs Disease [C18.452.584.687.803.350.300.850]
- Metabolism, Inborn Errors [C18.452.648]
- Brain Diseases, Metabolic, Inborn [C18.452.648.189]
- Lysosomal Storage Diseases, Nervous System [C18.452.648.189.435]
- Sphingolipidoses [C18.452.648.189.435.825]
- Gangliosidoses [C18.452.648.189.435.825.300]
- Gangliosidoses, GM2 [C18.452.648.189.435.825.300.300]
- Tay-Sachs Disease [C18.452.648.189.435.825.300.300.500]
- Lipid Metabolism, Inborn Errors [C18.452.648.398]
- Lipidoses [C18.452.648.398.641]
- Sphingolipidoses [C18.452.648.398.641.803]
- Gangliosidoses [C18.452.648.398.641.803.350]
- Gangliosidoses, GM2 [C18.452.648.398.641.803.350.300]
- Tay-Sachs Disease [C18.452.648.398.641.803.350.300.850]
- Lysosomal Storage Diseases [C18.452.648.595]
- Lysosomal Storage Diseases, Nervous System [C18.452.648.595.554]
- Sphingolipidoses [C18.452.648.595.554.825]
- Gangliosidoses [C18.452.648.595.554.825.300]
- Gangliosidoses, GM2 [C18.452.648.595.554.825.300.300]
- Tay-Sachs Disease [C18.452.648.595.554.825.300.300.840]
Below are MeSH descriptors whose meaning is more specific than "Tay-Sachs Disease".
This graph shows the total number of publications written about "Tay-Sachs Disease" by people in this website by year, and whether "Tay-Sachs Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tay-Sachs Disease" by people in Profiles.
-
Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor a. Cells. 2023 Dec 08; 12(24).